Azacitidine
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-01 — Genomic Evolution of Myeloproliferative Neoplasms and Therapy-Associated Mutagenesis.: Longitudinal WGS study (observational): azacitidine exposure produces a distinct C>G-enriched mutational signature in MPN blood cells, directly documenting therapy-associated mutagenesis in vivo. (novelty: 4)
Open questions
Related
Contributing findings
Genomic Evolution of Myeloproliferative Neoplasms and Therapy-Associated Mutagenesis.
01-sep-2026
novelty 4
per-area 4
introduces